Search

Your search keyword '"Lee, Hae-Young"' showing total 1,680 results
Start Over Author "Lee, Hae-Young"
1,680 results on '"Lee, Hae-Young"'

2. Efficacy of an Electronic Health Management Program for Patients With Cardiovascular Risk: Randomized Controlled Trial

Author

Yun, Young Ho, Kang, EunKyo, Cho, Young Min, Park, Sang Min, Kim, Yong-Jin, Lee, Hae-Young, Kim, Kyae Hyung, Lee, Kiheon, Koo, Hye Yeon, Kim, Soojeong, Rhee, YeEun, Lee, Jihye, Min, Jeong Hee, and Sim, Jin-Ah

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundIn addition to medication, health behavior management is crucial in patients with multiple risks of cardiovascular mortality. ObjectiveThis study aimed to examine the efficacy of a 3-month Smart Management Strategy for Health–based electronic program (Smart Healthing). MethodsA 2-arm randomized controlled trial was conducted to assess the efficacy of Smart Healthing in 106 patients with at least one indicator of poor disease control and who had hypertension, diabetes, or hypercholesterolemia. The intervention group (n=53) took part in the electronic program, which was available in the form of a mobile app and a Web-based PC application. The program covered 4 areas: self-assessment, self-planning, self-learning, and self-monitoring by automatic feedback. The control group (n=53) received basic educational material concerning disease control. The primary outcome was the percentage of participants who achieved their clinical indicator goal after 12 weeks into the program: glycated hemoglobin (HbA1c)

Published
2020
Full Text
View/download PDF

3. Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.

Author

Kim, Eui-Soon, Park, Sun-Kyeong, Youn, Jong-Chan, Lee, Hye, Lee, Hae-Young, Cho, Hyun-Jai, Choi, Jin-Oh, Jeon, Eun-Seok, Lee, Sang, Kim, Min-Seok, Kim, Jae-Joong, Hwang, Kyung-Kuk, Cho, Myeong-Chan, Chae, Shung, Kang, Seok-Min, Park, Jin, Choi, Dong-Ju, Yoo, Byung-Su, Cho, Jae, Kim, Kye, Oh, Byung-Hee, Greenberg, Barry, and Baek, Sang

Subjects
Cost-Effectiveness Analysis, Drug Therapy, Empagliflozin, Heart Failure, SGLT2 Inhibitors, United States, Humans, Heart Failure, Cost-Effectiveness Analysis, Prospective Studies, Stroke Volume, Republic of Korea
Abstract

BACKGROUND: The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved empagliflozin for reducing cardiovascular mortality and heart failure (HF) hospitalization in patients with both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). However, limited data are available on the generalizability of empagliflozin to clinical practice. Therefore, we evaluated real-world eligibility and potential cost-effectiveness based on a nationwide prospective HF registry. METHODS: A total of 3,108 HFrEF and 2,070 HFpEF patients from the Korean Acute Heart Failure (KorAHF) registry were analyzed. Eligibility was estimated by inclusion and exclusion criteria of EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) and EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) trials and by FDA & EMA label criteria. The cost-utility analysis was done using a Markov model to project the lifetime medical cost and quality-adjusted life year (QALY). RESULTS: Among the KorAHF patients, 91.4% met FDA & EMA label criteria, while 44.7% met the clinical trial criteria. The incremental cost-effectiveness ratio of empagliflozin was calculated at US$6,764 per QALY in the overall population, which is far below a threshold of US$18,182 per QALY. The cost-effectiveness benefit was more evident in patients with HFrEF (US$5,012 per QALY) than HFpEF (US$8,971 per QALY). CONCLUSION: There is a large discrepancy in real-world eligibility for empagliflozin between FDA & EMA labels and clinical trial criteria. Empagliflozin is cost-effective in HF patients regardless of ejection fraction in South Korea health care setting. The efficacy and safety of empagliflozin in real-world HF patients should be further investigated for a broader range of clinical applications. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01389843.

Published
2024

6. Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea

Author

Kim, Eui-Soon, Park, Sun-Kyeong, Cho, Daniel Sung-ho, Youn, Jong-Chan, Lee, Hye Sun, Lee, Hae-Young, Cho, Hyun-Jai, Choi, Jin-Oh, Jeon, Eun-Seok, Lee, Sang Eun, Kim, Min-Seok, Kim, Jae-Joong, Hwang, Kyung-Kuk, Cho, Myeong-Chan, Chae, Shung Chull, Kang, Seok-Min, Park, Jin Joo, Choi, Dong-Ju, Yoo, Byung-Su, Cho, Jae Yeong, Kim, Kye Hun, Oh, Byung-Hee, Greenberg, Barry, and Baek, Sang Hong

Published
2024
Full Text
View/download PDF

8. Impact of a Telehealth Program With Voice Recognition Technology in Patients With Chronic Heart Failure: Feasibility Study

Author

Lee, Heesun, Park, Jun-Bean, Choi, Sae Won, Yoon, Yeonyee E, Park, Hyo Eun, Lee, Sang Eun, Lee, Seung-Pyo, Kim, Hyung-Kwan, Cho, Hyun-Jai, Choi, Su-Yeon, Lee, Hae-Young, Choi, Jonghyuk, Lee, Young-Joon, Kim, Yong-Jin, Cho, Goo-Yeong, Choi, Jinwook, and Sohn, Dae-Won

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundDespite the advances in the diagnosis and treatment of heart failure (HF), the current hospital-oriented framework for HF management does not appear to be sufficient to maintain the stability of HF patients in the long term. The importance of self-care management is increasingly being emphasized as a promising long-term treatment strategy for patients with chronic HF. ObjectiveThe objective of this study was to evaluate whether a new information communication technology (ICT)–based telehealth program with voice recognition technology could improve clinical or laboratory outcomes in HF patients. MethodsIn this prospective single-arm pilot study, we recruited 31 consecutive patients with chronic HF who were referred to our institute. An ICT-based telehealth program with voice recognition technology was developed and used by patients with HF for 12 weeks. Patients were educated on the use of this program via mobile phone, landline, or the Internet for the purpose of improving communication and data collection. Using these systems, we collected comprehensive data elements related to the risk of HF self-care management such as weight, diet, exercise, medication adherence, overall symptom change, and home blood pressure. The study endpoints were the changes observed in urine sodium concentration (uNa), Minnesota Living with Heart Failure (MLHFQ) scores, 6-min walk test, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) as surrogate markers for appropriate HF management. ResultsAmong the 31 enrolled patients, 27 (87%) patients completed the study, and 10 (10/27, 37%) showed good adherence to ICT-based telehealth program with voice recognition technology, which was defined as the use of the program for 100 times or more during the study period. Nearly three-fourths of the patients had been hospitalized at least once because of HF before the enrollment (20/27, 74%); 14 patients had 1, 2 patients had 2, and 4 patients had 3 or more previous HF hospitalizations. In the total study population, there was no significant interval change in laboratory and functional outcome variables after 12 weeks of ICT-based telehealth program. In patients with good adherence to ICT-based telehealth program, there was a significant improvement in the mean uNa (103.1 to 78.1; P=.01) but not in those without (85.4 to 96.9; P=.49). Similarly, a marginal improvement in MLHFQ scores was only observed in patients with good adherence (27.5 to 21.4; P=.08) but not in their counterparts (19.0 to 19.7; P=.73). The mean 6-min walk distance and NT-proBNP were not significantly increased in patients regardless of their adherence. ConclusionsShort-term application of ICT-based telehealth program with voice recognition technology showed the potential to improve uNa values and MLHFQ scores in HF patients, suggesting that better control of sodium intake and greater quality of life can be achieved by this program.

Published
2017
Full Text
View/download PDF

9. The Efficacy and Tolerability of Irbesartan/Amlodipine Combination Therapy in Patients With Essential Hypertension Whose Blood Pressure Were not Controlled by Irbesartan Monotherapy

Author

Lee, Hae-Young, Min, Kyung Wan, Han, Kyung Ah, Kim, Jeong Su, Ahn, Jeong Cheon, Kim, Moo Hyun, Lee, Jin Bae, Shin, Sung-Hee, Kim, Chong-Jin, Kim, Kye Hun, Cho, Deok-Kyu, Choi, Junghyun, Rhee, Moo-Yong, Her, Sung-Ho, Kim, Weon, Na, Jin Oh, Cho, Goo-Yeong, Kim, Seok Yeon, Park, Gyung-Min, Lee, Bong-Ki, Jo, Sang-Ho, Lee, Byung Wan, Sohn, Il-Suk, Kim, Doo-Il, Ihm, Sang-Hyun, Lee, Sun Hwa, Chung, Joong-Wha, Cho, Eun Joo, Son, Jang Won, Oh, Seung-Jin, Hwang, Jin-Yong, Jeong, Jin-Ok, Han, Kyoo-Rok, Yoon, Hyuck-Jun, Seo, Suk Min, Chung, Wook-Jin, Bae, Jang-Whan, Choi, Jin-Ho, Hyun, Bok Jin, Cha, Ji Eun, Yoo, Seung Ji, and Shin, Jinho

Published
2024
Full Text
View/download PDF

20. Expert Consensus on the Clinical Use of Pulse Wave Velocity in Asia

Author

Park, Jeong Bae, Sharman, James E, Li, Yan, Munakata, Masanori, Shirai, Kohji, Chen, Chen-Huan, Jae, Sae Young, Tomiyama, Hirofumi, Kosuge, Hisanori, Bruno, Rosa Maria, Spronck, Bart, Kario, Kazuomi, Lee, Hae Young, Cheng, Hao-Min, Wang, Jiguang, Budoff, Matthew, Townsend, Raymond, and Avolio, Alberto P

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Aging, Bioengineering, Heart Disease, Prevention, Cardiovascular, Clinical Research, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Arterial stiffness, Pulse wave velocity, Cardiovascular disease, Asia, Cardiovascular medicine and haematology, Clinical sciences
Abstract

Arterial stiffness is a progressive aging process that predicts cardiovascular disease. Pulse wave velocity (PWV) has emerged as a noninvasive, valid, and reliable measure of arterial stiffness and an independent risk predictor for adverse outcomes. However, up to now, PWV measurement has mostly been used as a tool for risk prediction and has not been widely used in clinical practice. This consensus paper aims to discuss multiple PWV measurements currently available in Asia and to provide evidence-based assessment together with recommendations on the clinical use of PWV. For the methodology, PWV measurement including the central elastic artery is essential and measurements including both the central elastic and peripheral muscular arteries, such as brachial-ankle PWV and cardio-ankle vascular index, can be a good alternative. As Asian populations are rapidly aging, timely detection and intervention of "early vascular aging" in terms of abnormally high PWV values are recommended. More evidence is needed to determine if a PWV-guided therapeutic approach will be beneficial to the prevention of cardiovascular diseases beyond current strategies. Large-scale randomized controlled intervention studies are needed to guide clinicians.

Published
2022

21. Metformin treatment is associated with improved survival in diabetic patients hospitalized with acute heart failure: A prospective observational study using the Korean acute heart failure registry data

Author

Chun, Kyeong-Hyeon, Oh, Jaewon, Lee, Chan Joo, Park, Jin Joo, Lee, Sang Eun, Kim, Min-Seok, Cho, Hyun-Jai, Choi, Jin-Oh, Lee, Hae-Young, Hwang, Kyung-Kuk, Kim, Kye Hun, Yoo, Byung-Su, Choi, Dong-Ju, Baek, Sang Hong, Jeon, Eun-Seok, Kim, Jae-Joong, Cho, Myeong-Chan, Chae, Shung Chull, Oh, Byung-Hee, and Kang, Seok-Min

Published
2024
Full Text
View/download PDF

39. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Author

Reid, Christopher, Schlaich, Markus, Katz, Ivor, Ajani, Andrew, Biswas, Sinjini, Esler, Murray, Elder, Grahame, Roger, Simon, Colquhoun, David, Mooney, John, De Backer, Tine, Persu, Alexandre, Chaumont, Martin, Krzesinski, Jean-Marie, Vanassche, Thomas, Girard, Ginette, Pliamm, Lew, Schiffrin, Ernesto, Merali, Fatima, Dresser, George, Vallee, Michel, Jolly, Shivinder, Chow, Stephen, Wang, Jiguang, Mu, Jianjun, Yu, Jing, Yuan, Hong, Feng, Yingqing, Zhang, Xin, Xie, Jianhong, Lin, Ling, Soucek, Miroslav, Widimsky, Jiri, Cifkova, Renata, Vaclavik, Jan, Ullrych, Martin, Lukac, Martin, Rychlik, Ivan, Guldager Lauridsen, Thomas, Kantola, Ilkka, Taurio, Jyrki, Ukkola, Olavi, Ormezzano, Olivier, Gosse, Philippe, Azizi, Michel, Courand, Pierre-Yves, Delsart, Pascal, Tartiere, Jean Michel, Mahfoud, Felix, Schmieder, Roland, Stegbauer, Johannes, Lurz, Philipp, Koziolek, Michael, Ott, Christian, Toursarkissian, Nicole, Tsioufis, Konstantinos, Kyfnidis, Konstantinos, Manolis, Athanasios, Patsilinakos, Sotirios, Zebekakis, Pantelis, Karavidas, Apostolos, Denes, Pall, Bezzegh, Katalin, Zsom, Marianna, Kovacs, Laszlo, Sharabi, Yehonatan, Elias, Mazen, Sukholutsky, Ivetta, Yosefy, Chaim, Kenis, Irina, Atar, Shaul, Volpe, Massimo, Maria Lorenza, Muiesan, Taddei, Stefano, Grassi, Guido, Veglio, Franco, Son, Jung Woo, Kim, Jang-Young, Park, Joong-Il, Lee, Chang Hoon, Lee, Hae-Young, Raugaliene, Rasa, Marcinkeviciene, Jolanta Elena, Kavaliauskiene, Roma, Deinum, Jaap, Kroon, Abraham, van den Born, Bert-Jan, Januszewicz, Andrzej, Tykarski, Andrzej, Walczewska, Jolanta, Gaciong, Zbigniew, Wiecek, Andrzej, Chrostowska, Marzena, Kleinrok, Andrzej, Krekora, Jan, Kania, Grzegorz, Podrazka-Szczepaniak, Anna, Golawski, Cezary, Podziewski, Maciej, Kaczmarek, Barbara, Skoczylas, Grzegorz, Wilkolaski, Andrzej, Wozniak, Iwona, Janik-Palazzolo, Marzena, Rewerska, Barbara, Konradi, Aleksandra, Shvarts, Yuriy, Pecherina, Tamara, Nikolaev, Konstantin, Liudmila, Gapon, Orlikova, Olga, Mordovin, Viktor, Petrochenkova, Natalia, Kamalov, Gadel, Kosmacheva, Elena, Tyrenko, Vadim, Gorbunov, Vladimir, Obrezan, Andrey, Supryadkina, Tatiana, Ler, Irina, Kotenko, Oleg, Kuzin, Anatoly, Martínez García, Fernando, Redon, Josep, Oliveras, Anna, Beltran Romero, Luis, Shatylo, Valerii, Rudenko, Leonid, Bazylevych, Andriy, Rudyk, Yurii, Karpenko, Oleksandr, Stanislavchuk, Mykola, Tseluyko, Vira, Kushnir, Mykola, Asanov, Ervin, Sirenko, Yuriy, Yagensky, Andriy, Collier, David, Gupta, Pankaj, Webb, David, MacLeod, Mary, McLay, James, Peace, Aaron, Arora, Samir, Buchanan, Patricia, Harris, Robert, Degarmo, Ronald, Guillen, Mario, Karns, Adam, Neutel, Joel, Paliwal, Yogesh, Pettis, Karlton, Toth, Phillip D., Wayne, Jeffrey M., Butcher, Michael Bain, Diller, Phillip M., Oparil, Suzanne, Calhoun, David, Brautigam, Donald, Flack, John, Goldman, Jesse M., Rashidi, Arash, Aslam, Nabeel, Haley, William, Andrawis, Nabil, Lang, Brian, Miller, Randy, Powell, James, Dewhurst, Robert, Pritchard, James, Khanna, Dinesh, Tang, Dennis, Gabra, Nashwa, Park, Jean, Jones, Conigliaro, Scott, Cranford, Luna, Blanca, Mussaji, Murtaza, Bhagwat, Ravi, Bauer, Michael, McGinty, John, Nambiar, Rajesh, Sangrigoli, Renee, Davis, William Ross, Eaves, William, McGrew, Frank, Awad, Ahmed, Bolster, Eric, Scott, David, Kalirao, Paramjit, Dabel, Pascal, Calhoun, Wesley, Gouge, Steven, Warren, Mark, Lawrence, Mary Katherine, Jamal, Aamir, El-Shahawy, Mohamed, Mercado, Carlos, Kumar, Jayant, Velasquez-Mieyer, Pedro, Busch, Robert, Lewis, Todd, Rich, Lisa, Schlaich, Markus P, Bellet, Marc, Weber, Michael A, Danaietash, Parisa, Bakris, George L, Flack, John M, Dreier, Roland F, Sassi-Sayadi, Mouna, Haskell, Lloyd P, Narkiewicz, Krzysztof, and Wang, Ji-Guang

Published
2022
Full Text
View/download PDF

47. A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Author

Jeon, Eun-Seok, Lim, Sang Wook, Kim, Seok-Yeon, Yang, Hyoung-Mo, Kim, Moo Hyun, Rhee, Moo-Yong, Han, Seung Hwan, Shin, Jinho, Kim, Kwang-il, Jeong, Jin-Ok, Sung, Ki Chul, Hong, Geu Ru, Kim, Hyung-Seop, Kwon, Kihwan, Kang, Tae-Soo, Lee, Hae-Young, and Han, Su-Eun

Published
2022
Full Text
View/download PDF

50. Correction: Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

Author

Choi, Dong-Ju, Park, Chan Soon, Park, Jin Joo, Lee, Hae-Young, Kang, Seok-Min, Yoo, Byung-Su, Jeon, Eun-Seok, Hong, Seok Keun, Shin, Joon-Han, Kim, Myung-A, Park, Dae-Gyun, Kim, Eung-Ju, Hong, Soon-Jun, Kim, Seok Yeon, and Kim, Jae-Joong

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results